Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-India, swamped by COVID-19 surge, fast-tracks approval of foreign vaccines

Tue, 13th Apr 2021 08:54

* India reports 161,736 new infections, total at 13.7 mln

* Deaths rise by 879 to 171,058

* India has administered more than 106 mln vaccine doses
(Adds details,)

By Alasdair Pal and Krishna N. Das

NEW DELHI, April 13 (Reuters) - India is to fast-track
emergency approvals for COVID-19 vaccines that have been
authorised by Western countries and Japan, paving the way for
possible imports of Pfizer, Johnson & Johnson,
and Moderna shots.

The move, which will drop the need for companies to do
small, local safety trials for their vaccines before seeking
emergency approval, follows the world's biggest surge in cases
in the country this month.

Vaccines authorised by the World Health Organization or
authorities in the United States, Europe, the United Kingdom and
Japan "may be granted emergency use approval in India, mandating
the requirement of post-approval parallel bridging clinical
trial", the health ministry said in a statement.

"The first 100 beneficiaries of such foreign vaccines shall
be assessed for seven days for safety outcomes before they are
rolled out."

India, the world's biggest maker of vaccines, has
administered more than 106 million doses of COVID-19 shots, but
many regions are now running short of supplies as inoculations
expand due to surging cases.

India has sold more than 54.6 million vaccine doses abroad
and gifted more than 10 million to partner countries.

It is currently using the AstraZeneca shot and a
homegrown vaccine developed by Bharat Biotech for its own
immunisation drive, and this week approved Russia's Sputnik V
shot for emergency use.

Since April 2, India has reported the world's highest daily
tallies of infections, topping 100,000 last week. It reported
161,736 cases on Tuesday, taking the total to 13.7 million.
Deaths rose by 879 to 171,058.

RALLIES, RELIGIOUS EVENTS

The jump in infections, for which Health Minister Harsh
Vardhan acknowledged widespread failure by citizens to heed
curbs on movement and social interaction as contributory
factors, has prompted calls for the government to cancel huge
public events.

But hundreds of thousands of devout Hindus are set to bathe
in the Ganges river on Wednesday, the third key day of a
weeks-long festival.

Nearly a million bathed in the Ganges on Monday in the
belief that its waters would wash away their sins. More than 100
tested positive for COVID-19, in random testing of around 18,000
attendees testing carried out by authorities, local media said.

Few at the mass religious gathering called the Kumbh Mela -
or pitcher festival - observed precautions such as social
distancing or mask wearing, Reuters witnesses said, and hundreds
of thousands more are expected to plunge into the waters in the
northern city of Haridwar on Wednesday.

Similar concerns were sparked by mass election rallies by
the ruling Bharatiya Janata Party and opposition parties during
polls in four states and one federally-run region. At one rally
in the eastern state of West Bengal, a key political prize, Home
Minister Amit Shah posted Twitter pictures of meetings with
crowds of supporters while unmasked.

DEADLY SPREAD

The second wave of infections, which began in India's major
cities, is increasingly spreading into the hinterland, where
healthcare facilities are often rudimentary.

In Raipur, the capital of Chhattisgarh state known for its
large tribal population, the main government hospital's morgue
was struggling to keep up with the number of deaths, said joint
director Dr Vineet Jain.

"All oxygenated and ICU beds are full in our set up," he
told Reuters.

"Around 50 dead bodies are laying, we have a shortage of
space. Some private hospitals do not have space to keep the dead
bodies so they also send the bodies to us."

Vardhan cited several reasons for the national surge.

"There have been elections, religious gatherings, reopening
of offices, lots of people travelling, attending social
functions, not following rules, little mask-wearing in functions
like weddings, even on crowded buses and trains," he told a
video conference last week.

India is currently reporting around double the daily cases
of the United States and Brazil, the two other worst affected
countries, though its daily death toll is lower.

India's total infections rank after only the United States,
having overtaken Brazil on Monday.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access/)

(Interactive graphic tracking global spread of coronavirus:
https://graphics.reuters.com/world-coronavirus-tracker-and-maps/)

(Reporting by Krishna N. Das and Alasdair Pal in New Delhi and
Jatindra Dash in Bhubaneswar; Editing by Nick Macfie, Ana
Nicolaci da Costa and John Stonestreet)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.